secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jasper Therapeutics, Inc. (JSPR)
CIK:        0001788028
Form:       8-K
Filed at:   2022-03-11T23:59:59+00:00
Accession:  0001213900-22-011854
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

William Lis steps down as CEO; Ronald Martell appointed President and CEO; Lis becomes Chairperson
--------------------------------------------------------------------------------

- William Lis terminates employment as CEO effective March 15, 2022; remains as Class III director and non-employee Chairperson for 12-month term.
- As Chairperson, Lis receives $250,000 annual fee; after board service, consulting at $12,250/month through later of 12 months or March 15, 2024.
- Lis will be granted option to purchase 100,000 shares of common stock, vesting monthly over 12 months commencing March 15, 2022.
- Prior employment agreement and severance plan terminated; if terminated without Cause, Lis receives continued annual fee and full option vesting.
- Ronald Martell appointed as President and CEO; specific compensation terms for Martell not disclosed in this filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1788028/000121390022011854/0001213900-22-011854-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1788028/000121390022011854/ea156711-8k_jasperther.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-011854

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer